Seres Therapeutics, Inc. Elects Dennis Ausiello, M.D., To Board Of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., a leading microbiome therapeutics platform company developing a novel class of Ecobiotic® drugs designed to treat disease by restoring the function of a dysbiotic microbiome, today announced that Dennis Ausiello, M.D., has been elected to the company's board of directors. Dr. Ausiello, the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Chair of Medicine, Emeritus at Massachusetts General Hospital (MGH), is an internationally acclaimed clinician who brings a wealth of academic and clinical experience in medicine to Seres.

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.